Skip to content
GLP-1 Clinics Nearby
Starting careJuly 24, 2026 · 9 min read

GLP-1 eligibility: what BMI, health history, and product labels mean

A BMI threshold can describe an FDA-approved use, but it cannot decide whether a medication is appropriate for you. Product, health history, current medicines, and follow-up all matter.

Edited by

· Co-founder & CTO, Savo Group

B.S. in Computer Science, Oregon State University · B.A. in Psychology, University of Washington, Seattle

GLP-1 eligibility consultation reviewing BMI, health history, and medication fit

Current status

A prescriber determines medical fit

Common label thresholds are a starting point. Eligibility, contraindications, warnings, and treatment goals require an individual clinical assessment.

Common adult threshold
BMI 30 or higher
Another label pathway
BMI 27+ with a related condition
BMI alone decides
No
At a glance

What an eligibility review is actually checking

BMI can open a label pathway, but the rest of the assessment determines whether a product may fit.

Swipe horizontally to compare →

What an eligibility review is actually checking. BMI can open a label pathway, but the rest of the assessment determines whether a product may fit.
Review areaWhy it mattersWhat it does not guarantee
BMI and related conditionsConnects the patient to a product’s labeled populationA prescription or insurance approval
Medical and family historySurfaces warnings, contraindications, and monitoring needsThat one medication is the automatic choice
Current medicines and goalsHelps evaluate interactions, fit, and a realistic care planA side-effect-free or permanent result

Table source:NIDDK prescription medications for overweight and obesity

01

The familiar BMI numbers come from product labeling

For chronic weight management in adults, FDA-approved products such as Wegovy and Zepbound include a pathway for adults with obesity, commonly described as a BMI of 30 or higher, and another for adults with overweight, commonly a BMI of 27 or higher, plus at least one weight-related condition. The exact indication belongs to the exact product—not to every medicine marketed under the broad “GLP-1” label.

Those numbers describe populations included in an approved use. They do not create an automatic prescription, guarantee insurance coverage, or show which product is the best fit. A prescriber still needs to assess the person rather than approve a checkout form.

02

Medical fit goes beyond height and weight

A useful assessment reviews why treatment is being considered, previous weight-management efforts, current medicines, allergies, relevant medical and family history, and pregnancy or pregnancy plans. Current product labeling also includes contraindications, warnings, and possible drug interactions that a short eligibility quiz may not capture.

The prescriber should know about diabetes treatment, prior pancreatitis or gallbladder concerns, digestive symptoms, kidney problems, eye disease related to diabetes, and any personal or family history relevant to the product label. This is not a complete screening list; the current label and clinical judgment control.

Do not omit health information to pass an online eligibility form. A safe program gives you a way to provide a complete history and ask questions before a prescription is issued.

03

What to bring to an eligibility visit

You do not need to arrive having chosen a medication. Bring the information that helps a clinician evaluate your options and explain what happens next.

  • A complete medication and supplement list, including diabetes medicines.
  • Relevant diagnoses, procedures, allergies, and family history.
  • Recent weight history and any available blood pressure or lab information.
  • Pregnancy, breastfeeding, or plans to become pregnant.
  • Your treatment goals, budget, insurance details, and preferred visit format.
  • Questions about product choice, side effects, monitoring, and stopping treatment.

04

Eligibility should lead to a care plan—not just a payment screen

A program should identify the clinician or medical group responsible for the assessment, explain how follow-up works, and name the product and dispensing pathway. It should also be clear how you report side effects, what monitoring may be needed, and what happens if the first option is not covered or tolerated.

Treat instant approval, a guaranteed prescription, or an offer that does not ask for meaningful medical history as a reason to slow down. Legitimate care may be convenient, but it is still clinical care.

Common questions

Answers to clarify the comparison

What BMI qualifies for a GLP-1 medication?
For some FDA-approved chronic weight-management products, common adult pathways are BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition. The exact product label and a prescriber’s assessment determine whether treatment is appropriate.
Can I qualify if my BMI is below 27?
A broad category page cannot determine that. Approved indications differ by product and medical purpose, and off-label prescribing is a clinical decision. Ask a qualified prescriber to explain the specific product, intended use, evidence, and alternatives.
Does meeting an FDA label threshold mean insurance will cover treatment?
No. Medical eligibility and benefit coverage are separate decisions. A plan may use its own formulary, prior-authorization criteria, and documentation requirements.

Primary sources

Read the official material behind this page

Health information is educational and does not diagnose, determine eligibility, or replace product labeling and care from a qualified professional.